GO:0031851 kappa-type opioid receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0031851 (kappa-type opioid receptor binding) is a molecular function defined as binding to a kappa-type opioid receptor, with synonyms dynorphin receptor binding and kappa-type opioid receptor ligand [1,2].
• Kappa-type opioid receptor binding sites were first characterized in guinea-pig cerebellum and later in rat and guinea-pig spinal cord, establishing a distinct pharmacological profile from mu and delta sites [1,4].
• The kappa-type opioid receptor is a member of the opioid receptor family, and its binding properties are modulated by mono- and divalent cations and cholinergic compounds [2,7].
• Selective kappa ligands such as U-69,593 have been used to define kappa binding sites and to study analgesic and intestinal effects in rats.
• Kappa-type opioid receptor binding is relevant to human tissues including placental membranes, indicating peripheral roles beyond the central nervous system.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models enable causal interrogation of genes encoding kappa-type opioid receptor binding proteins and their ligands.
Description
GO:0031851, kappa-type opioid receptor binding, is a molecular function term in the Gene Ontology that describes the binding of a ligand or protein to a kappa-type opioid receptor [1,2]. This term captures a critical interaction in opioid pharmacology, where the kappa receptor is one of the three classical opioid receptor types (mu, delta, and kappa) that mediate the effects of endogenous opioid peptides and synthetic opioids. The kappa-type opioid receptor binding function is distinct from mu- and delta-type binding, as demonstrated by early radioligand binding studies in guinea-pig cerebellum and spinal cord [1,4]. Researchers study this term to understand how endogenous ligands such as dynorphin and synthetic kappa-selective compounds interact with the receptor, and how these interactions influence analgesia, mood, and peripheral physiology [6,8]. The kappa-type opioid receptor binding function has been characterized in multiple species and tissues, including guinea-pig cerebellum, rat and guinea-pig spinal cord, and human placental membranes [1,3,4]. These studies established that kappa binding sites exhibit a unique pharmacological profile, with selective ligands such as U-69,593 showing high affinity for kappa sites over mu and alpha sites. The modulation of binding by ions and cholinergic compounds further highlights the complexity of kappa-type opioid receptor binding as a regulated molecular function. Understanding GO:0031851 is therefore essential for researchers investigating opioid receptor biology, pain, addiction, and peripheral opioid effects.
kappa-type opioid receptor binding At A Glance
| GO ID | GO:0031851 |
|---|---|
| GO term | kappa-type opioid receptor binding |
| Ontology | molecular_function |
| Synonym | dynorphin receptor binding; kappa-type opioid receptor ligand |
| Major function | Binding to a kappa-type opioid receptor |
| Tissue distribution | Characterized in guinea-pig cerebellum, rat and guinea-pig spinal cord, and human placental membranes [1,3,4] |
| Selective ligands | U-69,593 interacts with kappa-opioid binding sites |
| Modulation | Binding is modulated by mono- and divalent cations and cholinergic compounds |
| Related receptor family | Opioid receptors including mu, delta, and kappa types |
What Is GO:0031851?
In our own words, GO:0031851 (kappa-type opioid receptor binding) is the molecular function of selectively and non-covalently interacting with a kappa-type opioid receptor. This includes the binding of endogenous opioid peptides such as dynorphin, as well as synthetic kappa-selective ligands, to the kappa receptor protein. The term is synonymous with dynorphin receptor binding and kappa-type opioid receptor ligand activity [1,2].
Why Is kappa-type opioid receptor binding Important in Cell Biology?
GO:0031851 is important because kappa-type opioid receptor binding is a key determinant of opioid pharmacology, influencing analgesia, mood regulation, and peripheral organ function. The kappa receptor is a validated target for pain and itch, and its binding profile distinguishes it from mu and delta receptors, which is critical for developing selective therapeutics with fewer side effects [2,8]. Early binding studies in guinea-pig cerebellum and spinal cord provided the foundation for understanding kappa receptor pharmacology [1,4], and the detection of kappa-type opioid receptors in human placental membranes suggests roles beyond the central nervous system. Moreover, the modulation of kappa binding by ions and cholinergic compounds indicates that this function is dynamically regulated, which has implications for drug design and for interpreting experimental results.
• Defines a distinct opioid receptor binding function separate from mu and delta binding [1,2].
• Provides a pharmacological target for kappa-selective analgesics such as U-69,593.
• Relevant to central nervous system processes including pain and nociception.
• Detected in peripheral tissues such as human placental membranes.
• Binding is modulated by cations and cholinergic compounds, indicating regulatory complexity.
• Serves as a basis for ex vivo labeling methods to study opioid receptor occupancy.
• Important for understanding species differences, as characterized in guinea-pig, rat, and human tissues [1,3,4].
• Enables structure-activity relationship studies of kappa-opioid ligands [6,8].
Molecular Mechanism of kappa-type opioid receptor binding
Ligand recognition and binding site architecture
In simple terms: The kappa receptor has a pocket that recognizes specific opioid molecules.
Kappa-type opioid receptor binding involves the recognition of ligands by a binding site within the kappa receptor protein. Early radioligand binding studies in guinea-pig cerebellum identified opioid binding sites of the kappa-type, establishing that these sites are distinct from mu and delta sites. The molecular characterization of opioid receptors confirmed that kappa receptors are members of the opioid receptor family and possess specific ligand-binding domains. Selective ligands such as U-69,593 interact with kappa-opioid binding sites with high affinity, as demonstrated in rat tissues.
Tissue-specific expression and binding profiles
In simple terms: Different tissues have different amounts and types of kappa binding sites.
Kappa-type opioid receptor binding sites have been characterized in multiple tissues. In guinea-pig cerebellum, kappa binding sites were identified and distinguished from other opioid sites. In rat and guinea-pig spinal cord, kappa-opioid binding sites were characterized, showing region-specific distribution. In human placental membranes, kappa-type opioid receptors were detected, indicating peripheral expression. These findings demonstrate that kappa-type opioid receptor binding is not restricted to the brain and can be studied in various experimental systems.
Modulation by ions and cholinergic compounds
In simple terms: Small molecules like ions can change how well kappa ligands bind.
The binding of ligands to kappa-type opioid receptors is modulated by mono- and divalent cations and by cholinergic compounds. Kosterlitz et al. (1988) showed that modulation of binding at opioid receptors by these agents affects receptor-ligand interactions. This indicates that kappa-type opioid receptor binding is not a static process but is subject to regulation by the ionic and cholinergic environment, which is important for interpreting binding assays and for understanding physiological regulation.
In vivo receptor occupancy and ex vivo labeling
In simple terms: Researchers can measure kappa binding in living animals and then in brain tissue.
In vivo opiate receptor binding of oripavines to mu, delta, and kappa sites in rat brain has been determined using an ex vivo labeling method. This approach allows the assessment of kappa-type opioid receptor binding after systemic administration of ligands, providing a bridge between in vitro binding data and in vivo pharmacology. Such methods are essential for understanding how kappa-type opioid receptor binding translates to physiological effects.
Ligand selectivity and pharmacological consequences
In simple terms: Some drugs bind more tightly to kappa receptors than to other opioid receptors.
The interaction of U-69,593 with mu-, alpha-, and kappa-opioid binding sites and its analgesic and intestinal effects in rats illustrates the pharmacological consequences of kappa-type opioid receptor binding. Helix-constrained nociceptin peptides have been developed as potent agonists and antagonists of ORL-1 and nociception, showing that peptide engineering can target opioid receptor binding functions. These studies highlight the importance of ligand selectivity in determining the physiological outcomes of kappa-type opioid receptor binding.
Key Genes Involved in GO:0031851 kappa-type opioid receptor binding
The following genes and proteins are directly implicated in kappa-type opioid receptor binding, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| OPRK1 | Encodes the kappa-type opioid receptor protein | Primary receptor for GO:0031851; target for binding assays [1,2] |
| PDYN | Encodes prodynorphin, precursor of dynorphin peptides | Endogenous ligand for kappa-type opioid receptor binding |
| OPRM1 | Encodes mu-type opioid receptor | Related opioid receptor; used to distinguish kappa binding [2,5] |
| OPRD1 | Encodes delta-type opioid receptor | Related opioid receptor; used to distinguish kappa binding [2,5] |
| OPRL1 | Encodes nociceptin receptor | Related opioid receptor family member; targeted by helix-constrained peptides |
| GNB1 | G protein beta subunit | Downstream signaling of kappa receptor binding |
| GNG2 | G protein gamma subunit | Downstream signaling of kappa receptor binding |
| ARRB1 | Beta-arrestin 1 | Regulates receptor desensitization after kappa binding |
| ARRB2 | Beta-arrestin 2 | Regulates receptor desensitization after kappa binding |
| KCNJ3 | G protein-activated inward rectifier potassium channel 1 | Effector of kappa receptor signaling |
| KCNJ6 | G protein-activated inward rectifier potassium channel 2 | Effector of kappa receptor signaling |
| CACNA1B | Voltage-dependent N-type calcium channel | Inhibited by kappa receptor activation |
| ADCY1 | Adenylyl cyclase 1 | Inhibited by kappa receptor activation |
| SLC6A4 | Serotonin transporter | Modulated by kappa opioid system |
| POMC | Proopiomelanocortin | Related opioid peptide precursor; context for opioid binding |
| PENK | Proenkephalin | Related opioid peptide precursor; context for opioid binding |
How Is kappa-type opioid receptor binding Regulated?
Kappa-type opioid receptor binding is regulated by several factors. Mono- and divalent cations and cholinergic compounds modulate binding at opioid receptors, as shown by Kosterlitz et al. (1988). The ionic environment can affect the affinity and efficacy of ligands at kappa sites. Additionally, receptor desensitization and internalization following agonist binding involve beta-arrestins and G protein-coupled receptor kinases, which are general regulatory mechanisms for opioid receptors. The presence of kappa-type opioid receptors in peripheral tissues such as human placental membranes suggests that local factors may also regulate binding. Overall, regulation of kappa-type opioid receptor binding is multifactorial and context-dependent.
kappa-type opioid receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| OPRK1 | Pain, addiction, mood disorders | OPRK1 knockout and point-mutation cell lines; ligand binding assays [1,2] |
| PDYN | Stress, addiction, pain | PDYN overexpression and knockout models; dynorphin binding studies |
| OPRM1 | Pain, opioid tolerance | OPRM1 knockout to isolate kappa binding [2,5] |
| OPRD1 | Pain, mood | OPRD1 knockout to isolate kappa binding [2,5] |
| OPRL1 | Nociception, stress | OPRL1 knockout and knock-in for peptide binding |
Pain and analgesia
Kappa-type opioid receptor binding is directly linked to analgesic effects. U-69,593, a selective kappa ligand, produces analgesic effects in rats, demonstrating that binding to kappa receptors can modulate pain pathways. The kappa opioid system is a target for developing pain therapeutics with potentially reduced abuse liability compared to mu opioids. Dysregulation of kappa binding may contribute to chronic pain states, and selective ligands are used to study these mechanisms [6,8].
Addiction and mood disorders
The kappa opioid system has been implicated in stress, mood, and addiction. Dynorphin, the endogenous ligand for kappa-type opioid receptor binding, is involved in stress responses and negative affect. Helix-constrained nociceptin peptides that target ORL-1 and nociception also interact with opioid systems, highlighting the interplay between kappa binding and emotional regulation. Alterations in kappa receptor binding may contribute to depression and substance use disorders, making GO:0031851 relevant to psychiatric research.
Peripheral and placental biology
Kappa-type opioid receptors have been detected in human placental membranes, indicating a role in peripheral physiology. The presence of kappa binding sites in the placenta suggests potential involvement in fetal development, maternal-fetal signaling, or placental function. This expands the disease relevance of GO:0031851 beyond the central nervous system to include reproductive and developmental biology.
Gastrointestinal and intestinal effects
Kappa opioid receptor binding also affects gastrointestinal function. U-69,593 has been shown to produce intestinal effects in rats, indicating that kappa binding can modulate gut motility. This has implications for opioid-induced constipation and for developing peripherally restricted kappa ligands. The study of kappa-type opioid receptor binding in the gut is therefore relevant to gastrointestinal disorders.
From kappa-type opioid receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does OPRK1 mediate kappa-type opioid receptor binding? | OPRK1 knockout cell line (CRISPR KO) |
| How do point mutations in OPRK1 affect ligand binding affinity? | OPRK1 point-mutation knock-in cell line |
| Can a tagged OPRK1 be used to track receptor localization? | Tagged OPRK1 knock-in (e.g., GFP or HA tag) |
| What is the effect of OPRK1 overexpression on downstream signaling? | OPRK1 overexpression stable cell line |
| Which genes regulate kappa receptor binding? | CRISPR library screening in OPRK1-expressing cells |
| How does PDYN processing affect kappa binding? | PDYN knockout and overexpression models |
How to Study the kappa-type opioid receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding assay | Affinity and density of kappa receptors | Characterizing kappa binding sites in tissues [1,4] |
| Ex vivo labeling | In vivo receptor occupancy | Assessing kappa binding after drug administration |
| Selective ligand competition | Ligand selectivity for kappa vs mu/delta | Pharmacological profiling of kappa ligands |
| Molecular cloning and expression | Receptor protein structure and function | Studying kappa receptor binding domains |
| Peptide engineering | Binding affinity of modified peptides | Developing kappa-selective agonists/antagonists |
| Ion modulation assays | Effect of cations on binding | Understanding regulation of kappa binding |
| CRISPR knockout | Causal role of genes in kappa binding | Validating OPRK1 and related genes |
| CRISPR knock-in | Effect of specific mutations on binding | Dissecting ligand-binding residues |
Radioligand binding assays
Radioligand binding assays are the classical method for studying kappa-type opioid receptor binding. Early studies used tritiated ligands to identify kappa binding sites in guinea-pig cerebellum and spinal cord [1,4]. These assays measure the affinity and density of kappa receptors in tissue homogenates or membrane preparations. Selective ligands such as U-69,593 are used to discriminate kappa sites from mu and delta sites. Ex vivo labeling methods allow the assessment of receptor occupancy after in vivo drug administration.
Ex vivo and in vivo labeling
Ex vivo labeling methods have been developed to determine in vivo opiate receptor binding of oripavines to mu, delta, and kappa sites in rat brain. This approach involves administering a ligand in vivo, then labeling remaining receptors ex vivo to quantify occupancy. It provides a bridge between in vitro binding data and in vivo pharmacology, and is useful for studying kappa-type opioid receptor binding in intact animals.
Molecular and pharmacological characterization
Molecular characterization of opioid receptors, including cloning and expression studies, has advanced the understanding of kappa-type opioid receptor binding. Pharmacological characterization using selective agonists and antagonists, such as helix-constrained nociceptin peptides, helps define the binding specificity and functional consequences. Modulation of binding by ions and cholinergic compounds can be studied using these methods.
CRISPR-based genetic models
CRISPR-Cas9 genome editing enables the creation of knockout, point-mutation, knock-in, and overexpression models to study kappa-type opioid receptor binding. Knockout of OPRK1 can abolish kappa binding, while point mutations can dissect ligand-binding residues. Tagged knock-in models allow visualization of receptor trafficking. These genetic approaches complement pharmacological methods and provide causal insights.
How CRISPR Can Be Used to Study GO:0031851 kappa-type opioid receptor binding
Knockout
CRISPR knockout of OPRK1 or other genes involved in kappa-type opioid receptor binding can abolish or reduce binding activity, providing causal evidence for gene function. For example, OPRK1 knockout cell lines can be used to confirm that kappa binding sites are encoded by this gene. Knockout of PDYN can reduce endogenous dynorphin levels, affecting kappa receptor activation.
Point Mutation
Point mutations introduced by CRISPR base editing or homology-directed repair can be used to dissect the ligand-binding pocket of the kappa receptor. Mutating specific residues predicted to contact ligands can alter binding affinity, as inferred from molecular characterization of opioid receptors. Such models help identify key determinants of kappa-type opioid receptor binding.
Knock-in
Knock-in of tagged OPRK1 (e.g., GFP or HA) allows real-time visualization of receptor localization and trafficking. Knock-in of disease-associated variants can model altered binding properties. These models are valuable for studying kappa-type opioid receptor binding in a physiological context.
Overexpression
Overexpression of OPRK1 or its ligands (e.g., PDYN) can enhance kappa-type opioid receptor binding signals, facilitating biochemical and signaling assays. Overexpression models are useful for screening compounds that modulate kappa binding and for studying downstream effects.
How EDITGENE Supports kappa-type opioid receptor binding Research
Researchers studying kappa-type opioid receptor binding-related genes often need to determine whether a candidate gene is causally involved in receptor binding, signaling, or downstream physiology. EDITGENE provides CRISPR-based cell models and screening services to enable such investigations with high specificity and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for kappa-type opioid receptor binding research.
Frequently Asked Questions About kappa-type opioid receptor binding
What is GO:0031851?
GO:0031851 is the Gene Ontology molecular function term for kappa-type opioid receptor binding, defined as binding to a kappa-type opioid receptor [1,2].
What genes are involved in kappa-type opioid receptor binding?
Key genes include OPRK1 (encoding the kappa receptor), PDYN (encoding dynorphin), and related opioid receptor genes such as OPRM1 and OPRD1.
What is the synonym for kappa-type opioid receptor binding?
Synonyms include dynorphin receptor binding and kappa-type opioid receptor ligand [1,2].
How is kappa-type opioid receptor binding measured?
It is commonly measured by radioligand binding assays using selective ligands such as U-69,593, and by ex vivo labeling methods [5,8].
Which tissues express kappa-type opioid receptors?
Kappa-type opioid receptors have been characterized in guinea-pig cerebellum, rat and guinea-pig spinal cord, and human placental membranes [1,3,4].
What is the role of U-69,593 in kappa binding?
U-69,593 is a selective ligand that interacts with kappa-opioid binding sites and produces analgesic and intestinal effects in rats.
How do ions affect kappa-type opioid receptor binding?
Mono- and divalent cations and cholinergic compounds modulate binding at opioid receptors, including kappa sites.
Is kappa-type opioid receptor binding involved in pain?
Yes, kappa receptor binding is linked to analgesia, as shown by the analgesic effects of U-69,593 in rats.
Can CRISPR be used to study kappa-type opioid receptor binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models can be used to dissect the function of OPRK1 and related genes.
What diseases are associated with kappa-type opioid receptor binding?
It is associated with pain, addiction, mood disorders, and peripheral conditions such as placental biology and gastrointestinal effects [2,3,8].
Conclusion
GO:0031851 (kappa-type opioid receptor binding) is a well-defined molecular function with a rich pharmacological history. From early radioligand binding studies in guinea-pig cerebellum and spinal cord to molecular characterization of opioid receptors, the kappa binding site has been distinguished from mu and delta sites and linked to analgesia, mood, and peripheral physiology [1,2,4]. Selective ligands such as U-69,593 and modulation by ions and cholinergic compounds further define this function [7,8]. Modern CRISPR-based models now enable causal interrogation of the genes and mechanisms underlying kappa-type opioid receptor binding, offering new opportunities for therapeutic development.
References
- 1. Robson LE et al.. 1984. Opioid binding sites of the kappa-type in guinea-pig cerebellum.. Neuroscience 12(2):621-7 PMID: 6087201
- 2. Loh HH et al.. 1990. Molecular characterization of opioid receptors.. Annu Rev Pharmacol Toxicol 30:123-47 PMID: 2160790
- 3. Ohta S et al.. 1989. [Kappa-type opioid receptor in human placental membrane].. Masui 38(10):1293-300 PMID: 2555580
- 4. Wood MS et al.. 1989. Characterisation of kappa-opioid binding sites in rat and guinea-pig spinal cord.. Neuropharmacology 28(10):1041-6 PMID: 2572992
- 5. Richards ML et al.. 1985. In vivo opiate receptor binding of oripavines to mu, delta and kappa sites in rat brain as determined by an ex vivo labeling method.. Eur J Pharmacol 114(3):343-53 PMID: 2998812
- 6. Lohman RJ et al.. 2015. Helix-constrained nociceptin peptides are potent agonists and antagonists of ORL-1 and nociception.. Vitam Horm 97:1-55 PMID: 25677767
- 7. Kosterlitz HW et al.. 1988. Modulation of binding at opioid receptors by mono- and divalent cations and by cholinergic compounds.. J Recept Res 8(1-4):363-73 PMID: 2838622
- 8. La Regina A et al.. 1988. Interaction of U-69,593 with mu-, alpha- and kappa-opioid binding sites and its analgesic and intestinal effects in rats.. Life Sci 42(3):293-301 PMID: 2826959
